C3b Receptor in Normal Human Skin  by Thyresson, Hakan N. et al.
0022-202X/ 81/7704-0353$02.00/ 0 
THE JOURNAL OF I N VESTIGATIVE DERM ATOLOG Y, 77:353-357 1981 
Copyright © 1981 by The Williams & Wilkins Co. 
Vol. 77. No.4 
Printed il1 U.S.A. 
C3b Receptor in Normal Human Skin 
HAKAN N. THYRESSON, M.D., FREDERIC C. McDUFFIE, M.D., AND ARNOLD L. SCHROETER, M.D. 
Departments of Dermatology, In.tern.al Medicine, and Immunology, Mayo Clinic, Mayo Foundation and Mayo M edical School, 
Rochester, Minnesota, U.S.A. 
Receptors for C3b in normal skin were studied. C3b 
was produced by treating normal human serum with 
cobra venom factor and by partial digestion of purified 
C3 vvith trypsin. Cryostat sections of normal human skin 
were incubated with C3b, followed by a direct immuno-
fluorescent technique using mono specific goat antihu-
man C3. The histologic localization of C3b fluorescence 
was ascertained by fixing cryostat sections with glutar-
aldehyde and staining with hematoxylin and eosin. The 
following structures showed staining with anti-C3: (1) 
endothelial cells in capillaries, larger vessels, and arter-
ies, (2) smooth muscle in arrector pilori muscles and 
artery walls, and (3) myoepithelial cells in the secretory 
portion of sweat glands. C3b did not bind to the inter-
cellular substance nor to the basement membrane zone 
in normal human skin. Normal human sera treated with 
EDTA, EGTA, and heat (56°C for 30 min) were negative, 
as was purified C3 by itself, thus indicating that native 
C3 did not bind to these receptors. Specificity for C31 
C3b was shown by blocking with both unconjugated 
rabbit antihuman C3 a nd purified C3. The endothelial 
C3b receptor may have an important role in the locali-
zation of immune complexes in cutaneous vasculitis. 
Many diseases affecting the skin h ave bee n expla ined as the 
result of deposition of complement-fixing immune complexes at 
the dermal-epidermal junction and in the wa lls of blood vessels. 
This concept developed from findings by direct immunofluores-
cen ce of in vivo depos ition of comple m ent compone nts and 
irnrnunoglobulins at these locations [1,2]. Many s uch patie n ts 
also have had d etectable circulating immune complexes, evi-
dence for consumption of complement, a nd low levels of com-
plement components or regulatory proteins [3]. T h e m ech anism 
by which immune complexes deposit in special locations such 
as t h e d ermal-epidermal junction and walls of cutaneous blood 
vessels is not known, but the recent observation of Gelfand, 
F rank, and Green [4], who reported the presence of C3b r ecep-
tors in glomerulal' endothelial cells, as weU as the loss of these 
receptor s ites in glomeruli of patients with immunologically 
mediated r e na l injury [5], suggested to u s the possibility that 
similar receptors a lso were present in s kin. Thus, the present 
s tudy was undertake n with the objective of determining 
w hether C3b r eceptors were present in normal human skin. 
METHODS 
Tissue 
Normal human skin was obtained from patients undergoing elective 
plastic surgery and from volunteers. Multiple cryostat skin sections 
from 6 different subj ects were examined. Biopsy specimens were taken 
from various sites on the upper and lower extremi ties, the a bdomen, 
and the chest wall. The specimens were immediately snap-frozen in 
liquid nitrogen and·stored at -70°C until used . Serial cryostat sections, 
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4 I-IITI thick, were cut fresh each working day. No air drying or fixatives 
were used. 
Preparation of C3 and C3b 
From normal human serum: Normal human serum was obtained 
from whole blood of 3 different healthy donors and was allowed to clot 
at room temperature for 60 min, after which the serum was sepru'ated 
by centrifugation, aliquoted in 0.1-m! volumes, and stored at -70°C 
un t il used. All sera were tested for levels of CH'50, C3, and the presence 
of smooth muscle or antimitochondrial ant ibodies; all of these were 
either within normal limits or negative. 
To produce C3b with co bra venom factor (Cordis Laboratories, 
Miami, FL) , a mixtw'e of cobra venom factor (1:2) and normal human 
serum (1:2) was allowed to react fo r 30 minutes at 37°C. The pH was 
then adjusted to between 7.1 and 7.3; EDTA was added to a concentra-
tion of 0.01 M , and the material was immediately used on tissue sect.ions. 
From purified C3: Lyophilized crysta lline trypsin (Worthington Bio-
chemical Company, Freehold, NJ) and soybean trypsin inhibitor (SBT!, 
Grand Island Biochemical Company), 7,200 units/ mg, were reconsti-
tut.ed in Veronal buffer , pH 7.6. P urified C3, 3.3 mg/ ml (a gift from Dr. 
H. J. Mi.iller-Eberhard, Scripps Clinic) , was treated with t rypsin in a 
ratio of C3 to tryps in of 100:1 wt/ wt for 120 seconds at 23°C. The 
digestion was stopped by adding a 2-fold weight excess of soybean 
trypsin inhibi tor (6]. Trypsin-prepared C3b was then allowed to react 
with tissue sections afte r the addition of 0.01 M EDTA. 
I mm.ufLofluorescence 
Cryostat sections were incubated for 20 min at 25°C with a source of 
C3 or C3b at a pH between 7.1 and 7.3 (7). T he slides were washed for 
10 min in phosphate- buffel'ed saline, pH 7.2, fo llowed by the addition 
of fluorescein-conjugated ant i-C:::. Aft.er additional washing, t he slides 
were mounted with coverslips in 10% phosphate-buffered saline and 
glycerin a nd examined the same day. 
Monospecific fluorescein-conjugated goat ant ihuman C3 (Hyland 
Laborato ries, F / P weigh t ratio 8.3 I-Lg/ mg, F / P molal' ratio 3.4, specifi c 
ant ibody concent ration 2.2 mg/ ml) was used in a dilution of 1:60 (36.6 
Ilg/ml). T he specificity was established by Ouchterlony immunodiffu-
sion and by blocking the a nti-C3 fluorescence with puri fied C3. Undi-
lu ted m bbit antihuman C3 (Bel1J'ings Diagnostics, t iter 1.3 mg/ ml) , 
puri fi ed C3 in a concentration of 0.21 mg/ ml, and normal human serum 
in a 1:128 dilution in 0.01 M EDTA as sources of native C3 were used in 
the blocking experiments. 
The localization of specific immunofluorescence could be directly 
evalua.ted by fix ing selected cryostat sections in 3% glu tamldehyde for 
30 min, fo llowed by staining wi th hematoxylin and eosin. Photographs 
of the exact same tissue sites were thus obtained. 
Microscope 
A Leitz Ortholux II UV-Epiluminator microscope was used. Excitor 
filter UGr (300 to 400 nm) and barrier filter (430 nm) were used. A 25x 
(luoride wa ter-immersion objective was used for screening, and a 50x 
fluoride water-immersion objective was used for photographing. After 
appropriate modification, the same microscope was used as a light 
microscope for examining and photographing sections stained with 
hematoxylin and eosin. 
Buffers 
The fo llowing buffers were used in the study: (1) glucose-gelatin 
Veronal buffer (gl-gvb++ 0.075), pH 7.4, for dilution of normal human 
serum and cobra venom factor; (2) Veronal buffer, pH 7.6, for the 
recon stitution of trypsin and soybean trypsin inhibi tor; and (3) phos-
phate-buffered saline, pH 7.2 to 7.3, for the washing of tissues, as one 
of the controls and to dilute (luorescein-conjugated antibody. 
Controls 
Phosphate-buffered saline and normal human serum treated with 
EGTA 0.01 M, EDTA 0.01 M, and heat inactiva tion (56°C for 30 min) 
were used as controls. 
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TABLE I. Immunofluorescent staining of normal human shin after 
incubation with serum treated with cobra venom factor 
Structure/cell 
Intercellular substance of epidermis 
DerIllal-epidermal basement membrane 
Smooth muscle 
Arterioles 
Arrector pilori muscles 
Endothelial cells of capillru-ies, venules, and ru·terioles 
Eccrine myoepithelial cells 
a Result of staining with goat FITC anti-C3 (1:60). 
Positive Tissue Control 
Results" 
Neg 
Neg 
++/ +++ 
++/ +++ 
++/ +++ 
++/+++ 
Tissue of normal human kidney was obtained from patients undergo-
ing nephrectomy. Specimens were immediately snap-frozen in liquid 
nitrogen and stored at -70°C until used. Serial cryostat sections 4-/.L1TI 
thick were cut fresh. No air drying or fixatives were used. Cryostat 
sections of normal human skin were also used, prepared as described 
above. Cryostat sections of both tissues were incubated for 20 min at 
25° C with a sow-ce of cobra venom factor-treated norma l human serum 
(see above, preparation of C3), as well as a source of cobra venom 
factor-treated normal human serum spontaneously decayed for 24 hr 
a t 37°C. Both sera were used at pH between 7.0 and 7.3. The slides 
were washed for 10 min in phosphate-buffered saline, pH 7.2, followed 
by the addition of fluorescein-conjugated anti-C3 (Hyland Laborato-
ries) and fluorescein-conjugated anti-IgG in a dilution of 1:20 (Behring 
Diagnostic Laboratories, F /P molar ratio 2, specific antibody concen-
trations 65 (Lg/ ml). After additional washing, the slides were mounted 
with coverslips in 10% phosphate-buffered saline and glycerin and 
examined the same day. 
RESULTS 
In preliminary experiments, we used inulin particles coated 
with C3b in order to detect C3b receptors but had difficulty in 
defining localization precisely. Normal human serum treated 
with cobra venom, followed by EDT A, proved to be a much 
better reagent_ EDT A was added because, in its absence, posi-
tive staining by serum not treated with cobra venom factor 
sometimes occw-red, owing to the conversion of C3 to C3b, 
probably by enzymes present in tissues [8]. Although staining 
of the dermal-epidermal junction was never seen, C3b receptors 
could be identified in arteriolar smooth muscle, the arrector 
pilori muscles of hair follicles, and the endothelial cells in the 
capillaries located in the dermis, papillary dermis, and around 
the sweat glands (Table I). Staining was also seen in the 
endothelial cells lining the lumina of venules and arterioles. In 
the secretory portion of eccrine sweat glands, the myoepithelial 
cells also showed positive fluorescence . 
Endothelial cells were brightly stained by serum treated with 
cobra venom factor but not by EDTA serum (Fig 1 A). The 
endothelial cell identification was demonstrated by comparison 
of the section stained using anti-C3 with the same one stained 
using hematoxylin and eosin (Fig 1 B). That the staining of 
capillary endothelial cells actually represented binding of C3b 
was demonstrated by the absence of binding of pw-ified C3 but 
binding to the endothelial cells of the same material converted 
to C3b by trypsin_ Positive staining was seen after treatment 
with trypsin-treated C3 but not with native C3 (Fig 2). Similar 
fluorescence was seen in the endothelial cells that lined the 
capillaries surrounding sweat ducts, small venules, and luteri-
FIe 1. Localization of receptors for C3b in capillary endothelium. A, 
Section of skin incubated with cobra venom-treated human serum 
followed by FITC anti-C3. A rrow indicates endothelial staining (x500). 
B, Same section stained with hematoxylin and eosin. Arrow indicates 
endothelium (X500). 
FIe 2. Incubation of skin section with trypsin-treated purified C3, 
followed by FITC anti-C3. Arrow indicates endothelial staining (x500) . 
FIe 3_ C3b fluorescence of endothelial cells of capillaries surround-
ing a sweat duct. S indicates lumen of duct; C indicates capillaries. 
FIe 4. Presence of receptors for C3b in ru-terial smooth muscle. A, 
Section incubated with normal human serum treated with cobra venom, 
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TABLE II. Immunofluorescent staining of normal human shin with 
purified C3 before and after treatment with trypsin 
Resul t" 
Structure/ cell 
Intercellulru' substance of epidermis 
Dermal-epidermal basement membrane 
Smooth muscle 
Arterioles 
Arrector pilori muscles 
Endothelial cells of capillaries, venules, and 
ru·terioles 
Incubation 
with 
purified 
C3 
Neg 
Neg 
Neg 
Neg 
Neg 
Eccrine myoepithelial cells Neg 
a Result of staining with goat FITC anti-C3 (1:60). 
Incubation 
with 
trypsinized 
C3 
Neg 
Neg 
+++ 
++++ 
++/ +++ 
++/ +++ 
'! ABLE III. Blocking experiments to demonstrate specificity of 
fluorescein-conjugated goat antihuman C3 
Firs t stage Second s tage Third s tage Resu lt 
Normal human skin in-
cubated with: 
Cobra venom- Rabbit anti-C3 Goat anti-C3 Neg 
tre cud serum (unconju- FITC (1:120) 
gated) 
Cobra venom- Saline Goat anti-C3 Pos 
treated serum FITC (1:120) 
Purified C3 Rabbit anti-C3 Goat anti-C3 Neg 
treated with (unconju- FITC (1:120) 
trypsin gated) 
Purified C3 Saline Goat anti-C3 Pos 
treated with FITC (1:120) 
trypsin 
Normal human skin Mixture of goat anti-
incuba ted with: C3 FITC (1:120) and: 
Cobra venom- Normal human Neg 
treated serum serum 1:128 
Cobra venom- Purified C3 Neg 
treated serum (0.21 mg/ ml) 
Cobra venom- Saline Pos 
treated serum 
oles, a nd smooth muscle in the vessel wall (Fig 3 and 4). The 
immunofluorescent pattern and histologic structure of the 
myoepithelial cells of the secretory portion of eccrine sweat 
glands, as well as the immunofluorescence of the arrector pilo-
rus muscle of a hair follicle, are shown in Fig 5. 
The fluorescent pattern of the endothelial cells of blood 
vessels consisted of linelu and wavy fluorescent streaks that 
appeared to represent sUlface staining, whereas the myoepithe-
lial cells of sweat glands and the smooth muscle cells of blood 
vessels and hair follicles showed a much more homogeneous 
pattern, consistent with staining of intracellular structUJ"es. 
However, it was not possible from immunofluorescent histology 
to localize staining precisely. The results with pw-ified C3 before 
and after treatment with trypsin duplicated those obtained with 
human serum (Table II). 
Unconjugated rabbit anti-C3 obtained from Behring Diag-
nostic Laboratories blocked staining by fluoresceinated goat 
followed by FITC anti-C3. S indicates staining of smooth muscle; C 
indicates staining of endothelium. B, Same section stained with hema-
toxylin and eosin. 
FIG 5. Presence of receptor for C3b in myoepithelial cells of eccrine 
sweat glands and arrector pilorus muscle. A, Section incubated with 
normal human serum treated with cobra venom, followed by FITC 
anti-C3. Arrow indicates myoepithelial cell fluorescence. B, Same sec-
tion stained with hematoxylin and eosin. Arrow indicates myoepithelial 
cell. C, C3b binding to ruTector pilori muscles. Section incubated with 
normal human serum treated with cobra venom, followed by FITC 
anti-C3. 
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TABLE IV. Control studies of immunofluorescent staining of normal 
human shin by anti·C3 to establish tissue binding of C3b but not C3 
Normal human skin incubated with: 
Normal human serum 1:4 (0.01 M EDTA) 
Normal human serum 1:4 (0.01 M EGTA) 
Normal human serum (56°C 30 min) 
Phosphate-buffered saline 
Normal human serum 1:4 treated with cobra 
venom fa ctor 
Goat anti·C3 
FITC (1:60) 
Neg 
Neg 
Neg 
Neg 
+++ 
TABLE V . Positive tissue control study: Immunofluorescent staining 
of normal human kidney glomeruli and normal human shin with 
fresh and decayed cobra venom factor· treated normal human sera 
First step Second step Kidney Human glomeruli skin 
Cobra venom-treated Goat anti·C3 Positive Positive 
serum FITC (1:60) 
Cobra venom-treated Goat anti-IgG Negative Negative 
serum FITC (1:20) 
Decayed cobra venom- Goat anti-C3 Negative Negative 
treated serum FITC (1:60) 
Normal human sera, Goat anti-C3 Negative Negative 
0.01 M EDTA FITC (1:60) 
Phosphate-buffered Goat anti-C3 Negative Negative 
saline FITC (1:60) 
-",... 
anti-C3 (Hyland Laboratories) of both C3b in serum and C3b 
obtained by trypsinization of C3 (Table III). Purified C3 in a 
concentration of 0.21 mg/ml and normal human serum in 
EDT A diluted 1: 128 both obliterated the fluorescence produced 
by 1:120 fluoresceinated goat anti-C3. All of these results estab-
lished the specificity ofthe direct immunofluorescent technique 
utilized in the present study. 
Endothelial cells, smooth muscle cells, or myoepithelial cells 
did not fluoresce if the first stage consisted of normal serum 
treated either with EDTA or with EGTA or by heating at 56°C 
for 30 rriin (Table IV). The goat anti-C3 conjugate by itself did 
not produce any staining. 
Receptors for C3b are known to be present on human kidney 
glomeruli; thus, this tissue is suitable to use as a positive control 
to demonstrate specificity of our immunofluorescence tech-
nique. Incubation of fresh cobra venom-treated normal human 
,serum on cryostat sections of kidney glomeruli showed positive 
staining demonstrated by fluorescein-conjugated anti-C3. Flu-
orescein-conjugated anti-IgG was als.o used to demonstrate that 
the staining is not due to an antibody. No positive staining 
could be demonstrated by fluorescein-conjugated anti-IgG. 
Cryostat sections of kidney glomeruli incubated with decayed 
cobra venom factor-treated normal human serum showed no 
binding to the glomeruli. The 'same experiments performed on 
cryostat sections of normal human skin gave results identical 
to those of the kidney glomeruli. The results of the positive 
tissue control are listed in Table V. 
Our results, blocking experiments, controls, and positive tis-
sue controls indicate that a receptor for C3 is present in normal 
human skin, and most likely the specific staining demonstrated 
in normal human skin is due to the C3b subcomponent. 
DISCUSSION 
Our study demonstrates the presence of C3b receptors of 
endothelial cells, smooth muscle cells, and myoepithelial cells 
of eccrine sweat glands. In an in vitro technique, C3b (produced 
by cobra venom factor treat · .ent of normal human serum and 
trypsin\zation of purified C3) showed binding to cryostat sec-
tions of normal human skin. . . 
Previously, C3b receptors have been found on the surface of 
a large number of circulating cells as well as to some extent on 
fixed cells. In the former category, such cells 'as B-Iymphocytes, 
erythrocytes, platelets [9], and neutrophilic granulocytes [10] 
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have been shown to possess C3b receptors on their surfaces; 
and among tissue cells, the Langerhans cells [11] and the rat 
mast cells [12] have similar receptors. 
The C3b receptor on these cells is involved in various func-
tions. Phagocytosis by polymorphonuclear leukocytes and mac-
rophages is enhanced by C3b receptors, and the receptor is also 
involved in the neutralization of viruses [13,14]. C3b present in 
immune complexes composed of T-Iymphocyte dependent an-
tigens and IgM antibody is believed to facilitate the binding of 
such complexes to B-Iymphocytes and monocytes via the mem-
brane receptor, thereby enhancing antibody production (15). 
Miller and Nussenzweig [16] have postulated that complement 
may regulate the interaction between immune complexes and 
cell membranes. They found that initially complement com-
ponents incorporated into immune complexes increased the 
affinity of the complexes for cell membranes. Subsequently, the 
immune complexes were converted to a nonbinding state by a 
mechanism involving the alternative complement pathway. 
Cell-bound complexes could be released from the cell mem-
brane by this second mechanism. 
Investigators who have studied the localization of immune 
complexes in tissues have postulated several possible ways by 
which they could be fixed. Among the factors that affect dep-
osition of immune complexes in blood vessels are high molecular 
weight ~nd release of histamine by basophils and platelets. 
Histamine increases the permeability of blood vessel walls, 
resulting in trapping of immune complexes [17,18]. In addition, 
size of blood vessels, turbulence, local damage to vessel walls, 
hypertension, and solubility of immune complexes also have a 
role in this process. Gelfand, Frank, and Green [4] reported the 
presence of C3b receptors on human glomerular endothelial 
cells and suggested that these receptors are responsible for the 
localization of circulating immune complexes in the kidney. 
Evidence supporting this concept was their subsequent finding 
that renal diseases characterized by the presence of circulating 
immune complexes and in vivo deposition of C3 were associated 
with a loss of receptor sites on' glomerular endothelium [5]. 
However, not all immune complexes found in tissues are derived 
from the circulation. Couser et al [19] and Couser et al [20] 
demonstrated that subepithelial tubular immune deposits can 
be produced in the isolated rat kidney by perfusion with specific 
antibody to rat proximal tubular epithelial cell brush border 
antigen in the absence of circulating immune complexes. Thus, 
deposition of immune complexes can result from in situ for-
mation rather than from circulation deposition. Electrophysical 
characteristics of the glomerular capillary wall may influence 
complex localization in the glomerular basement membrane. 
Our study did not demonstrate a C3 receptor present at the 
dermal-epidermal junction. Immune deposits at this location 
are frequently seen in diseases with circulating immune com-
plexes such as systemic lupus erythematosus (SLE). In SLE, 
localization of such immune complexes may be due to binding 
of DNA in the complexes by collagen receptors, with the 
subsequent deposition of antibody or trapping of immune com-
plex mechanically [21]. 
In the interim, before our results were published, a study by 
Schreiber and Penny [22] noted negative results in human skin. 
We believe that the authors used a technique that was too 
insensitive to be able to detect potential C3b receptors in 
human skin, namely fluorescein-labeled S. typhi coated with 
C3b, as well as autopsy specimens. Ow' technique is far more 
sensitive and useful for human skin, in which the density of 
receptors most likely is less than that of kidney glomeruli. We 
also made a special effort to obtain fresh tissue for our experi-
ments. The difference in technique may explain ow- positive 
findings. 
Our finding of a C3b receptor of the endothelial cells in 
capillaries and in arterioles and venules may be of importance 
in the localization of immune complexes at these sites and may 
have an important role in the immunopathogenesis of the 
cutaneous vasculitides in which circulating immune complexes 
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have a major role. Evidence for such a role has been demon-
strated in the animal models of the Arthus reaction and serum 
sickness [23]. Immunoglobulins and complement components 
also h ave been demonstrated by direct immunofluorescence 
studies in the cutaneous vessels in both early and late lesions of 
vasculitis [24). The C3b endothelial receptor may provide the 
anchor by which immune complexes initially localize to these 
tissues, followed by subsequent release of C3a and C5a, with 
attraction of granulocytes and liberation of histamine leading 
to vessel injury. C3b receptors on endothelial cells probably are 
widespread throughout the body. 
The finding that C3b also binds to smooth muscle in the 
arrector pilori muscles, arterioles, and myoepithelial cells was 
unexpected. We have not yet established whether C3b is bound 
to surface or intracellular sites in smooth muscle and myoepi-
thelial cells of eccrine sweat glands. Binding to these cells may 
be related to their content of myofibrils. The histologic pattern 
of C3b binding to these structures is suggestive of an intracel-
lular localization (Fig 4 and 5) . 
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